JO
ECYT

John Overdeck’s Endocyte, Inc. Common Stock ECYT Stock Holding History

John Overdeck’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-68,777
Closed -$97K – 3613
2017
Q3 		$97K Buy
+68,777
New +$95.8K ﹤0.01% 2654
2017
Q2 		– Sell
-31,641
Closed -$81K – 3461
2017
Q1 		$81K Sell
31,641
-23,369
-42% -$54.1K ﹤0.01% 2802
2016
Q4 		$140K Buy
+55,010
New +$158K ﹤0.01% 2960

Other funds holding ECYT

PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's ECYT Position: Q4 2017 in Review

John Overdeck sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 68,777 shares — an estimated $97K sold.

John Overdeck first reported a position in ECYT in Q4 2016 and held it in 3 quarters. The position peaked at $140K in Q4 2016. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

  • John Overdeck reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • John Overdeck sold 68,777 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $97K.
  • John Overdeck first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 3 quarters.
  • John Overdeck's Endocyte, Inc. Common Stock position peaked at $140K in Q4 2016.
  • 71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on Two Sigma Investments's 13F filing for Q4 2017, filed 14 Feb 2018.